Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HEC53856 in Healthy Volunteers
NCT03886688Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC53856 in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Incidence of Adverse Events. Started May 2019; status: completed.
02
Drugs
HEC53856
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03886688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886688.